Pharming Group N.V. Logo

Pharming Group N.V.

PHARM | AS

Overview

Corporate Details

ISIN(s):
NL0010391025 (+1 more)
LEI:
724500DCJ9MPG74JEH91
Country:
Netherlands
Address:
Darwinweg 24, 2333CR Leiden
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Pharming Group N.V. is a global biopharmaceutical company dedicated to developing and commercializing innovative treatments for patients with rare, debilitating, and life-threatening diseases. The company's portfolio focuses on protein replacement therapies and precision medicines designed to address significant unmet medical needs. By concentrating on both development and commercialization, Pharming aims to provide transformative therapies to underserved patient populations worldwide.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Pharming Group N.V.. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-07-31 08:23
Earnings Release
Pharming Group reports second quarter and first half 2025 financial results and…
Dutch 669.6 KB
2025-07-31 08:23
Earnings Release
Pharming Group reports second quarter and first half 2025 financial results and…
English 589.3 KB
2025-07-31 07:16
Earnings Release
Pharming Group N.V., Halfjaarlijkse financiële verslaggeving
English 589.3 KB
2025-06-24 07:35
Regulatory News Service
Pharming Group to host webcast on findings of a new study published in Cell adv…
Dutch 290.6 KB
2025-06-24 07:35
Regulatory News Service
Pharming Group to host webcast on findings of a new study published in Cell adv…
English 260.5 KB
2025-06-12 07:44
Post-Annual General Meeting Information
Pharming Group reports on results of the 2025 Annual General Meeting of Shareho…
Dutch 182.9 KB
2025-06-12 07:44
Post-Annual General Meeting Information
Pharming Group reports on results of the 2025 Annual General Meeting of Shareho…
English 176.9 KB
2025-05-01 06:28
Pre-Annual General Meeting Information
Pharming Group announces the 2025 Annual General Meeting of Shareholders and th…
English 182.9 KB
2025-04-23 09:44
Environmental & Social Information
Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as…
English 296.9 KB
2025-04-03 07:26
Annual Report (ESEF)
Pharming Group N.V., Jaarlijkse financiële verslaggeving
English 25.3 MB
2025-03-04 15:29
Post-Annual General Meeting Information
Pharming Group reports on results of the 2025 Extraordinary General Meeting of …
Dutch 224.7 KB
2025-03-04 15:29
Board/Management Information
Pharming Group reports on results of the 2025 Extraordinary General Meeting of …
English 224.4 KB
2025-02-21 07:38
M&A Activity
Pharming Technologies B.V. vergroot haar belang in Abliva AB (publ) naar 92,70 …
Dutch 254.4 KB
2025-02-21 07:38
M&A Activity
Pharming Technologies B.V. increases its ownership in Abliva AB (publ) to 92.70…
English 284.0 KB
2025-02-10 07:36
M&A Activity
Pharming Technologies B.V. declares unconditional and completes the recommended…
Dutch 272.1 KB

Automate Your Workflow. Get a real-time feed of all Pharming Group N.V. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Pharming Group N.V. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2020-12-23 S. de Vries Non-Executive member Other 4,200,000 N/A
2020-05-15 P. Sekhri Non-Executive member Buy 80,000 108,800.00 EUR
2020-05-15 P. Sekhri Non-Executive member Other 80,000 N/A
2019-05-23 S. de Vries Non-Executive member Other 800,000 N/A
2019-05-22 P. Sekhri Non-Executive member Other 50,000 N/A
2019-03-11 S. de Vries Non-Executive member Other 186,110 N/A
2019-01-30 S. de Vries Non-Executive member Other 201,050 N/A
2018-07-26 S. de Vries Non-Executive member Other 4,800,000 N/A
2018-07-26 S. de Vries Non-Executive member Sell 3,300,000 4,785,000.00 EUR
2018-07-26 S. de Vries Non-Executive member Buy 2,400,000 804,000.00 EUR

Peer Companies

Company Country Ticker View
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden ACUC
Advicenne Logo
Develops and commercializes therapies for rare renal diseases for patients of all ages.
France ALDVI
AegirBio AB Logo
Makes saliva-based diagnostics accessible for at-home & pro health & drug monitoring.
Sweden AEGIR
Aelis Farma Logo
Developing novel CB1 receptor inhibitors for treating brain and CNS disorders.
France AELIS
AGRONOMICS LIMITED Logo Isle of Man ANIC
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark ALK